Researchers cig-nal their faith in AI by taking up smoking

Palantir CTO Shyam Sankar claimed that some AI researchers smoke to signal faith that AI will eventually cure cancer, describing the behavior as “mass psychosis”; the article provides no independent confirmation of how widespread it is. A former cancer researcher said developing and introducing a cancer drug can take several years even with AI, and that tumor resistance may still emerge. The article also notes that a prediction of AI-designed pills becoming available in 2025 has not yet materialized.

Analysis

Signal quality: low. This is a reputational anecdote, not evidence of a change in AI capability, healthcare regulation, or commercial demand. The investable question is narrower: whether investors continue to price AI-enabled drug discovery on timelines that clinical development and health-system adoption cannot meet. If those timelines slip, the likely second-order effect is weaker financing and lower valuations for AI-drug-discovery ventures; established drug developers could gain bargaining leverage over tools and partnerships. That is a sector mechanism, not evidence of a near-term earnings benefit to any named company.

For Alphabet (GOOG), the comments around DeepMind’s drug-discovery ambitions are a reminder that scientific milestones do not automatically translate into approved, adopted, revenue-generating treatments. Watch for independently validated clinical results and commercial deployments rather than executive forecasts. The article provides no basis for revising Alphabet earnings. For Palantir (PLTR), its CTO’s remarks create a modest reputational headline, but there is no demonstrated link here to customer demand or contract risk.

Horizon: In the next few days, expect little fundamental price impact; any reaction is more likely narrative-driven. Over 1–3 months, watch AI-healthcare announcements and investor expectations for tangible milestones. Over 6–18 months, clinical validation, safety, resistance, and adoption timelines—not belief or rhetoric—will determine whether AI discovery supports durable economics.

Contrarian view: Skepticism about cure timelines is warranted, but failure to deliver a near-term cancer cure would not by itself disprove narrower productivity gains in target identification or research workflows. The article is too weak to justify a directional trade.

Key Decisions for Investors

• No trade on this article alone. Do not translate a culture-war anecdote into a change in GOOG or PLTR earnings estimates.
• For GOOG, treat AI drug-discovery claims as a catalyst watch: require independently verifiable clinical evidence or evidence of commercial adoption before assigning meaningful incremental value. Reassess if milestones slip materially or guidance begins to rely on near-term healthcare monetization.
• For PLTR, monitor whether the CTO’s comments prompt customer, employee, or partner concerns; absent evidence of commercial fallout, regard the reputational risk as contained rather than a short thesis.
• If AI-healthcare valuations re-rate, distinguish companies with validated clinical or workflow outcomes from those whose value rests mainly on projected discovery acceleration. A material clinical failure, safety signal, or adoption delay would strengthen the downside case; repeatable validated results would falsify it.